What question did this study set out to answer?

This research aims to explore how the MIF-CD74 axis influences colorectal cancer progression through metabolic changes.

April 24, 2026Cellular Oncology0 citationsOpen Access

The MIF-CD74 axis drives colorectal cancer via glycolytic reprogramming and is targeted by a novel small-molecule inhibitor

JLJinwei LouChina Pharmaceutical University YCYuhan ChenPediatric Oncology Group YLYue LiChina Pharmaceutical University

Key Points

This research aims to explore how the MIF-CD74 axis influences colorectal cancer progression through metabolic changes.
Investigation of the MIF-CD74 signaling pathway in colorectal cancer cells.
Assessment of glycolytic activity in cancer cell models.
Evaluation of a small-molecule inhibitor targeting the MIF-CD74 axis.
MIF-CD74 axis significantly promotes glycolytic reprogramming in colorectal cancer cells.
The small-molecule inhibitor effectively reduces cancer progression in preclinical models.

Abstract

This study elucidates a novel mechanism by which the MIF-CD74 axis drives CRC progression through glycolytic reprogramming and provides robust preclinical evidence for developing MIF-targeted therapies.

AI से पूछें

Bookmark

View Full Paper